175,000 Shares of Avantor, Inc. $AVTR Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC acquired a new stake in shares of Avantor, Inc. (NYSE:AVTR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 175,000 shares of the company’s stock, valued at approximately $2,634,000. Avantor accounts for about 1.6% of Sivik Global Healthcare LLC’s holdings, making the stock its 27th largest holding.

Several other institutional investors and hedge funds have also modified their holdings of AVTR. NorthCrest Asset Manangement LLC grew its stake in Avantor by 59.7% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 28,487 shares of the company’s stock worth $438,000 after acquiring an additional 10,644 shares during the period. GAMMA Investing LLC raised its holdings in Avantor by 9.5% in the 3rd quarter. GAMMA Investing LLC now owns 51,035 shares of the company’s stock valued at $768,000 after acquiring an additional 4,443 shares during the last quarter. Elevation Wealth Partners LLC lifted its stake in shares of Avantor by 72.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock worth $42,000 after purchasing an additional 1,176 shares during the period. Moody National Bank Trust Division purchased a new position in shares of Avantor during the 3rd quarter worth $1,810,000. Finally, Versant Capital Management Inc lifted its stake in shares of Avantor by 56.1% during the 3rd quarter. Versant Capital Management Inc now owns 14,163 shares of the company’s stock worth $213,000 after purchasing an additional 5,090 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Stock Up 0.5%

Avantor stock traded up $0.07 during trading on Tuesday, reaching $15.56. 1,180,025 shares of the company’s stock were exchanged, compared to its average volume of 10,054,715. Avantor, Inc. has a 52-week low of $7.26 and a 52-week high of $16.38. The firm has a market cap of $10.53 billion, a price-to-earnings ratio of -18.53, a PEG ratio of 11.83 and a beta of 0.94. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. The company’s 50-day moving average is $14.71 and its two-hundred day moving average is $11.19.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts predict that Avantor, Inc. will post 0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AVTR shares. TD Cowen raised their price objective on Avantor from $15.00 to $17.00 and gave the stock a “hold” rating in a report on Tuesday. Royal Bank Of Canada raised their price target on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Citigroup raised their target price on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Barclays upped their price target on shares of Avantor from $13.00 to $15.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 7th. Finally, Jefferies Financial Group raised shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price target on the stock in a research note on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Avantor presently has a consensus rating of “Hold” and an average price target of $13.24.

Avantor Company Profile

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.